Rosacea
Conditions
Interventions
Clecigabine treated group:Oral Clecigabine 20mg Once Daily
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign the informed consent form; 2. Age >= 18 years; 3. Patients who has undergone at least 12 weeks (or more) of oral treatment with any first-line medication such as antibiotics (doxycycline/minocycline/clarithromycin/azithromycin) or hydroxychloroquine, with or without other therapies (e.g., topical medications/IPL, etc.), and exhibits treatment resistance (manifested as no reduction of erythema by 1 grade, or erythema grade >= 3, or symptoms such as flushing affecting quality of life [DLQI moderate or above]); 4. Patients who experiences frequent relapses during the 12-week treatment period;
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant in the near future; 2. Patients with systemic diseases such as diabetes, moderate to severe liver, kidney, pulmonary, or hematological disorders; 3. Patients with depression or mental disorders; 4. Patients with chronic pancreatitis; 5. Patients with rosacea accompanied by nasal hyperplasia and hypertrophy, or with other facial dermatological conditions (such as seborrheic dermatitis, eczema, etc.), or facial manifestations of other diseases (such as dermatomyositis, systemic lupus erythematosus); 6. Individuals engaged in occupations such as driving, working at heights, or operating complex machinery; 7. Patients expected to be unable to adhere to follow-up; 8. Individuals who have participated in any clinical trial within the past month; 9. Patients with known allergies to the investigational drug or its excipients; 10. Patients deemed by the investigator to be unsuitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flushing Assessment Scale Tool (FAST); | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression Anxiety Stress Scales - 21 Item (DASS-21);Clinician Erythema Assessment (CEA);VISIA Erythema Index;Rosacea Quality of Life Index (RosaQoL); | — |
Countries
China
Contacts
Public ContactYue Zheng
Southern Medical University Southern Hospital
Outcome results
None listed